Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neurofibromatosis 1 3Neurofibromatoses 2Neurofibroma 2Melanoma 2Glioma 2Colorectal Neoplasms 2Breast Neoplasms 2Vascular Malformations 1Solid Tumor, Adult 1Skin Diseases, Vascular 1Primary Malignant Peripheral Nerve Sheath Tumors 1Oligodendroglioma 1Neurofibroma, Plexiform 1Neurocytoma 1Neoplasms, Neuroepithelial 1NF1 1Multiple Myeloma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1KRAS Mutant Non-Small Cell Lung Cancer 1Glioblastoma 1Ganglioneuroma 1Ganglioglioma 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorouracil 218Leucovorin 201Oxaliplatin 191Irinotecan 148Bevacizumab 107Capecitabine 93Cetuximab 89Folfox protocol 54Chemotherapy, Adjuvant 34Panitumumab 30pembrolizumab 23Nivolumab 22Colonoscopy 22Gemcitabine 20Magnetic Resonance Spectroscopy 19Floxuridine 19IFL protocol 18Celecoxib 18Radiotherapy 17Neoadjuvant Therapy 17Early Intervention, Educational 17Drug Therapy 17Laparoscopy 14Cyclophosphamide 14Counseling 14trifluridine tipiracil drug combination 13regorafenib 13XELOX 13Exercise 13Erlotinib Hydrochloride 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Colonic Neoplasms × mirdametinib × Clear all
NCT00147550 2013-09-13

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Pfizer

Phase 1/2 Terminated
79 enrolled
BreastDermatologicGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡